(provided by candidate): This is a submission of an application for a mentored patient-oriented K-23 award, designed to enhance clinical training and research expertise in the area of major depressive disorder on (MDD) and the role of natural remedies in the development and treatment of depressive disorders. Natural remedies, although used for centuries throughout the world, have become increasingly popular in the US over the past few years. S-adenosyl methionine (SAMe) is one such compound. Although results obtained from double-blind preliminary studies support the hypothesis that this compound may have antidepressant effects, oral SAMe has not yet been studied as a potential augmenting agent for contemporary, first-line antidepressants, such as the Selective Serotonin Reuptake Inhibitors (SSRIs). As many as 29% to 46% of depressed patients show only partial or non-response to an adequate course of an antidepressant, with most patients taking an SSRI as an initial treatment. The goal of this project will be to assess the efficacy of oral SAMe compared to placebo as an augmentor of SSRIs in the treatment of major depression refractory to treatment with SSRIs. This application involves enrolling outpatients with MDD, with partial or no response to an SSRI trial of adequate dose and duration. Patients will be treated for 6 weeks in a double-blind fashion with either oral SAMe tosylate, up to 1600mg/day, or placebo for 6 weeks. We hypothesize that there will be a statistically significant difference in the response rates between the two treatment groups at endpoint, with a greater response rate in the group that received SAMe augmentation. The proposed study will be based at the Massachusetts General Hospital in the Depression Clinical and Research Program, under the mentorship of Maurizio Fava, MD, and will include consultation from experts in the area of MDD, alternative medicine, and biostatistics. There will also be a didactic component to the application project, including coursework research design, neuronal biology, biostatistics, and ethics. It is hoped that this project award will provide the critical fund of basic knowledge and practical experience necessary to aid the candidate in becoming an independent investigator in this area.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Mentored Patient-Oriented Research Career Development Award (K23)
Project #
5K23MH069629-04
Application #
7143010
Study Section
Interventions Research Review Committee (ITV)
Program Officer
Chavez, Mark
Project Start
2004-01-27
Project End
2008-11-30
Budget Start
2006-12-01
Budget End
2007-11-30
Support Year
4
Fiscal Year
2007
Total Cost
$178,166
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Dording, C M; Mischoulon, D; Shyu, I et al. (2012) SAMe and sexual functioning. Eur Psychiatry 27:451-4
Mischoulon, David; Alpert, Jonathan E; Arning, Erland et al. (2012) Bioavailability of S-adenosyl methionine and impact on response in a randomized, double-blind, placebo-controlled trial in major depressive disorder. J Clin Psychiatry 73:843-8
Papakostas, George I; Mischoulon, David; Shyu, Irene et al. (2010) S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry 167:942-8
Papakostas, George I; Fava, Maurizio; Thase, Michael E (2008) Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biol Psychiatry 63:699-704
Shelton, Richard C; Papakostas, George I (2008) Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder. Acta Psychiatr Scand 117:253-9
Papakostas, G I; Homberger, C H; Fava, M (2008) A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. J Psychopharmacol 22:843-8
Papakostas, George I; Nelson, J Craig; Kasper, Siegfried et al. (2008) A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Eur Neuropsychopharmacol 18:122-7
Papakostas, George I; Stahl, Stephen M; Krishen, Alok et al. (2008) Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies. J Clin Psychiatry 69:1287-92
Papakostas, George I; Trivedi, Madhukar H; Alpert, Jonathan E et al. (2008) Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: a meta-analysis of individual patient data from 10 double-blind, randomized clinical trials. J Psychiatr Res 42:134-40
Papakostas, George I; Crawford, Christine M; Scalia, Margaret J et al. (2007) Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. A replication of findings with the use of a double-blind, placebo-controlled trial of Hypericum perforatum versus fluoxetine. Neuropsychobiology 56:132-7

Showing the most recent 10 out of 26 publications